Ripretinib Becomes the First Unregistered Drug in Mainland China Approved for the Named Patient Program Outside the Pilot Zone of Hainan Province - SC Read more about Ripretinib Becomes the First Unregistered Drug in Mainland China Approved for the Named Patient Program Outside the Pilot Zone of Hainan Province - SC
国家药品监督管理局受理瑞派替尼(Ripretinib)用于晚期胃肠道间质瘤治疗的新药上市申请 Read more about 国家药品监督管理局受理瑞派替尼(Ripretinib)用于晚期胃肠道间质瘤治疗的新药上市申请
再鼎医药和Turning Point宣布就Repotrectinib达成大中华区独家授权合作 Read more about 再鼎医药和Turning Point宣布就Repotrectinib达成大中华区独家授权合作
“Biotechnology in the Time of COVID-19”新书出版，杜莹博士携手全球数十位生物技术思想领袖分享抗疫观点 Read more about “Biotechnology in the Time of COVID-19”新书出版，杜莹博士携手全球数十位生物技术思想领袖分享抗疫观点
再鼎医药宣布首位中国患者入组用于评估Sulbactam-Durlobactam治疗碳青霉烯耐药的不动杆菌感染的全球3期临床研究ATTACK Read more about 再鼎医药宣布首位中国患者入组用于评估Sulbactam-Durlobactam治疗碳青霉烯耐药的不动杆菌感染的全球3期临床研究ATTACK